HG106, recently known as a potent SLC7A11 inhibitor, also showed marked tumor suppression and prolonged survival in the preclinical mouse models of KRAS-mutated lung adenocarcinoma [51]. This evidence concerns the gene SLC7A11 and lung adenocarcinoma.